Neurocrine Q2 EPS Crushes Estimates by 113%, Raises INGREZZA Sales Guidance
NBIX sits 52% above its 52-week low of $122.138.
Summary
Neurocrine Biosciences delivered a massive Q2 beat: adjusted EPS of $2.85 versus the $1.34 consensus, driven by 39% revenue growth to $954.3 million. INGREZZA sales rose 15% year-over-year on record prescriptions, and the newly acquired VYKAT XR contributed $54 million since the Soleno deal closed in May. Management raised full-year INGREZZA guidance to $2.825-$2.875 billion, signaling confidence in sustained demand. The stock is trading near its 52-week high, and this print reinforces the growth narrative following the transformative Soleno acquisition. With CRENESSITY also showing strong uptake and 80% reimbursement, the portfolio is firing on all cylinders. The magnitude of the earnings surprise and guidance raise demands immediate attention from traders.
At the time of this announcement, NBIX was trading at $185.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $18.7B. The 52-week trading range was $122.14 to $186.12. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.